Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NVCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovoCure reports Q2 revenue up 16% to $184M, raises 2026 guidance, receives EU approval for Optune Pax
Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 net revenues of $183.6M, up 16% YoY, driven by 18% global active patient growth to 5,128 patients; gross margin improved to 78% (vs. 74% prior year) including a one-time $4.9M tariff refund.
Exhibit 99.1 view on EDGAR → -
high
Raised full-year 2026 revenue guidance to $710-725M (from $690-710M) and Adjusted EBITDA guidance to $0-15M (from negative $15-0M), reflecting stronger patient growth and profitability trajectory.
Exhibit 99.1 view on EDGAR → -
high
Received CE Mark approval in June 2026 for Optune Pax in Europe for locally advanced pancreatic cancer; Germany will be first EU market to launch. U.S. had 285 active Optune Pax patients as of June 30.
Exhibit 99.1 view on EDGAR → -
medium
Optune Lua active patients grew 51% YoY to 207; Optune Gio active patients grew 11% to 4,636. Company expects FDA decision on brain metastases indication and completion of Phase 3 KEYNOTE D58 enrollment in Q4 2026.
Exhibit 99.1 view on EDGAR →
Summary
NovoCure reported strong second-quarter results with revenue growth accelerating to 16% year-over-year on the back of 18% global active patient growth across its TTFields therapy portfolio. The company raised its full-year revenue and profitability guidance, signaling confidence in sustained momentum.
Gross margin expansion to 78% (aided by a one-time tariff refund) and positive Adjusted EBITDA of $10.8M demonstrate improving operating leverage as the business scales. The CE Mark approval for Optune Pax in Europe represents a meaningful commercial expansion, opening a new geographic market for the pancreatic cancer indication that launched in the U.S. earlier this year.
With 285 active U.S. patients already on Optune Pax and a 51% year-over-year surge in Optune Lua patients, the company is diversifying its revenue base beyond the core glioblastoma franchise. The raised guidance assumes mid-to-high single-digit growth from Optune Gio and a $20-30M collective contribution from the newer indications, suggesting management sees a clear path to the higher revenue range. Upcoming catalysts include a Q4 FDA decision on the brain metastases indication and completion of Phase 3 enrollment in newly diagnosed glioblastoma, both of which could further expand the addressable market.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
NovoCure announced Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On July 23, 2026, the Company issued a press release announcing certain financial results for the quarter ended
June 30, 2026.
NovoCure disclosed financial results for the second quarter of 2026 ending June 30, 2026. The 8-K body does not provide specific figures; detailed results are contained in the attached press release (Exhibit 99.1), which was not provided for analysis.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Total net revenues for the quarter were $183.6 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by active patient growth globally.
NovoCure reported Q2 2026 net revenues of $183.6 million, up 16% year-over-year, driven by 18% global active patient growth. The company achieved a 78% gross margin (vs. 74% prior year), benefiting from a one-time $4.9 million tariff refund. Net loss was $15.7 million ($0.13 per share), and Adjusted EBITDA was $10.8 million positive.
Added in current filing · view on EDGAR →
Total net revenue: $710 million - $725 million (previous: $690 million - $710 million) ... Adjusted EBITDA*: $0 million - $15 million (previous: $(15) million - $0 million)
NovoCure raised full-year 2026 net revenue guidance to $710-725 million from $690-710 million, and Adjusted EBITDA guidance to $0-15 million from negative $15-0 million. The guidance includes $20-30 million collective contribution from Optune Lua and Optune Pax, and assumes mid-to-high single digit growth from Optune Gio with consistent quarterly gross margin in the mid-70s percent.
Added in current filing · view on EDGAR →
As of June 30, 2026, there were 5,128 total active patients on TTFields therapy globally. ... As of June 30, 2026, there were 4,636 active patients on Optune Gio, an increase of 11% from the same period in 2025. ... As of June 30, 2026, there were 207 active patients on Optune Lua, an increase of 51% from the same period in 2025.
NovoCure reported 5,128 total active patients globally as of June 30, 2026. Optune Gio active patients grew 11% year-over-year to 4,636, while Optune Lua active patients surged 51% to 207. Optune Pax had 285 active patients in the U.S. The U.S. contributed 2,725 total active patients, with Germany, France, and Japan contributing 675, 472, and 617 respectively.
Added in current filing · view on EDGAR →
Decision by the U.S. Food and Drug Administration on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from non-small cell lung cancer (Q4 2026). ... Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma (Q4 2026).
NovoCure expects an FDA decision on its premarket approval application for TTFields therapy to treat brain metastases from non-small cell lung cancer in Q4 2026. The company also anticipates completing enrollment in its Phase 3 KEYNOTE D58 trial for newly diagnosed glioblastoma in Q4 2026.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 24, 2026 · How we verify